Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01175-6
Abstract: Purpose. Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple levels of signal transduction may improve… read more here.
Keywords: combination; inhibitor; cediranib selumetinib; advanced solid ... See more keywords